Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare supply manufacturers for the Yangtze River Delta Alliance volume-based procurement (VBP) tender. The tender involves Shanghai, Zhejiang, and Anhui, and the platform has also disclosed the prices of the winning bids and spare products.
Tender Specifications and Procurement Cycle
The 44 specifications involved in the tender are all winning bids from the second to fourth national VBP rounds, with the exception of valsartan and amlodipine II/oral regular dosage form. The procurement cycle will commence from the actual implementation date of the winning results and will conclude at the end of 2025. During this period, medical institutions are required to prioritize the winning bids and ensure the completion of the agreed procurement volume.
Winning Manufacturers and Supply Arrangements
The majority of the winning manufacturers are domestic companies, including Kelun Pharma, Qilu Pharma, Chia Tai Tianqing, and Hengrui Medicine. International players such as Bayer’s Glucobay (acarbose) and Fresenius Kabi’s propofol medium and long chain fat emulsion also secured winning spots. For spare supply, both Anhui and Zhejiang will be supported by domestic manufacturers, while Shanghai has designated Sandoz as its only foreign spare supplier for simvastatin.-Fineline Info & Tech
